Despite numerous clinical trials, CAR-T therapy remains ineffective against solid tumors due to poor T-cell infiltration, antigen heterogeneity, and an immunosuppressive tumor microenvironment (TME). Traditional in vitro and animal models fail to accurately replicate these key barriers, limiting the ability to select promising CAR-T candidates for clinical translation.Our vessel-cancer co-culture model provides a physiologically relevant, scalable system for evaluating CAR-T migration, tumor infiltration, and cytotoxicity in a controlled TME-integrated microfluidic platform.Key Features of the Model:Vessel-Tumor Co-Culture – Integrates a perfusable endothelial vessel adjacent to a solid tumor compartmentT Cell Extravasation & Infiltration – Models CAR-T movement from vasculature to tumor tissueScalable Microfluidic Platform – Supports high-throughput drug and therapy screeningLive Imaging & Real-Time Tracking – Fluorescently labeled CAR-T cells enable dynamic monitoringCustomizable Tumor Microenvironment – Supports cancer cell lines, primary tumors, and immune modulators